Login
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc.

harmonybiosciences.com

What Do They Do?

Sells WAKIX, a narcolepsy medicine, through specialty distributors and develops treatments for sleep disorders, rare epilepsy and other neurological diseases.

How Do They Make Money?

Harmony sells WAKIX to specialty distributors; each product sale counts when the medicine is delivered to the buyer.

FY2025 revenue

Who Are Their Customers?

Harmony sells WAKIX to a limited number of specialty distributors, which then distribute it to patients.

Customers above 10% of revenue, FY2025
of revenue from three customers (38%, 36%, 26%)
FY2023: 100% from three customers

Do Revenues Turn Into Profits?

Yes. It kept 18 cents of every revenue dollar as net income in FY2025 and turned 40 cents into free cash flow.

Operating income, FY2025
24% of revenue
▲ +9% vs FY2024 ($190.8M, 27%)
Net income, FY2025
18% of revenue
▲ +9% vs FY2024 ($145.5M, 20%)
Free cash flow, FY2025
40% of revenue
▲ +59% vs FY2024 ($218.7M, 31%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +12%
vs $239.5M in Q3 FY2025
Net income
▼ −5%
vs $50.9M in Q3 FY2025
  • Aug 4, 2026 Reiterates full-year WAKIX revenue guidance The guidance is $1.0 billion to $1.04 billion.
  • Jul 16, 2026 CFO Glenn Reicin steps down; interim financial officer appointed Stephen Mollichella was appointed interim principal financial officer.
  • May 7, 2026 Reaffirms full-year WAKIX revenue guidance of $1.0 billion to $1.04 billion
  • Apr 14, 2026 Appoints Glenn Reicin as chief financial officer Sandip Kapadia was stepping down from the role.

Growing. Revenue grew 2.8x in 4 years, from $305.4M in FY2021 to $868.5M in FY2025, about 30% a year.

Broader development portfolio Earlier reports centered on pitolisant, with a preclinical asset under study for metabolic effects; the latest report also describes an orexin-based candidate, rare-epilepsy candidates and cell-replacement research.

Who Do They Compete With?

Competes with Jazz Pharmaceuticals, Axsome, Avadel Pharmaceuticals, Alkermes, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Aardvark Therapeutics, Rhythm Pharmaceuticals, Palobiofarma, Avidity Biosciences, Vertex Pharmaceuticals, Entrada Therapeutic, PepGen, UCB, Biocodex, Eisai, Janssen, GlaxoSmithKline, Assertio Holdings, and Stoke Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support